Focus Partners Wealth
VIR icon

Focus Partners Wealth’s Vir Biotechnology VIR Stock Holding History

Focus Partners Wealth’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.4K Buy
+10,088
New +$80.4K ﹤0.01% 2526
2025
Q3 		– Sell
-18,447
Closed -$93K – 2318
2025
Q2 		$93K Sell
18,447
-870
-5% -$4.67K ﹤0.01% 1949
2025
Q1 		$125K Buy
19,317
+2,566
+15% +$22.8K ﹤0.01% 1800
2024
Q4 		$123K Sell
16,751
-29,683
-64% -$234K ﹤0.01% 1780
2024
Q3 		$348K Buy
+46,434
New +$403K ﹤0.01% 1282

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Focus Partners Wealth's VIR Position: Q1 2026 in Review

Focus Partners Wealth opened a new position in Vir Biotechnology (VIR) in Q1 2026: 10,088 shares worth $90.4K. The stake represents ﹤0.01% of the portfolio and ranks #2526 among its holdings. This is a return to the name: Focus Partners Wealth previously reported a position in VIR as recently as Q2 2025.

Focus Partners Wealth first reported a position in VIR in Q3 2024 and has held it in 5 quarters since. The position peaked at $348K in Q3 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Focus Partners Wealth held 10,088 shares of Vir Biotechnology worth $90.4K as of Q1 2026.
  • Vir Biotechnology was a new Focus Partners Wealth position in Q1 2026.
  • Vir Biotechnology made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2526 holding.
  • Focus Partners Wealth first reported a position in Vir Biotechnology in Q3 2024 and has held it in 5 quarters since.
  • Focus Partners Wealth's Vir Biotechnology position peaked at $348K in Q3 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.